No Data
No Data
ABVC BioPharma Receives $296,000 Cash Out of Potential Aggregate License Fee of $24M Cash and Stock From Its Licensees AiBtl, ForSeeCon and OncoX in Global Licensing Deals
ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, a
ABVC Biopharma Files to Sell 1M Shares of Common Stock for Holders
ABVC BioPharma Receives First Cash Licensing Payment Anticipating $5 Million in Revenue
Express News | ABVC Biopharma- Under Terms of Deal, ABVC Grants Oncox Exclusive Rights for One of Abvc’s Four Products in Its Oncology Pipeline
Express News | ABVC Biopharma- ABVC & Unit Are Eligible to Receive Aggregate License Fee of $12.5 Mln in Form of Cash or Shares of Oncox Securities
Express News | ABVC Biopharma- Co & Biolite Entered Into Definitive Agreement With Oncox Biopharma to Collaborate on Combination Therapy
No Data